UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Association of HLA-DRB115 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort

European journal of neurology, 2011-10, Vol.18 (10), p.1258-1262

2011

Volltextzugriff (PDF)

Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study)

Journal of neurology, 2010-09, Vol.257 (9), p.1500-1507

2010

Volltextzugriff (PDF)

Effect of glatiramer acetate (Copaxone ®) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: A longitudinal study

Neuroscience letters, 2006-10, Vol.406 (3), p.270-275

2006

Volltextzugriff (PDF)

HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population

European journal of neurology, 2011-02, Vol.18 (2), p.337-342

2011

Volltextzugriff (PDF)

Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS

Neurology, 2004-01, Vol.62 (2), p.282-284

2004

Volltextzugriff (PDF)

Anticipation of age at onset in familial multiple sclerosis

European journal of neurology, 2010-04, Vol.17 (4), p.572-575

2010

Volltextzugriff (PDF)

Multiple sclerosis and cognitive decline: is ApoE-4 a surrogate marker?

Acta neurologica Scandinavica, 2011-10, Vol.124 (4), p.258-263

2011

Volltextzugriff (PDF)

Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases

Multiple sclerosis, 2006-04, Vol.12 (2), p.169-173

2006

Volltextzugriff (PDF)

MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS

Neurology, 2001-04, Vol.56 (8), p.1084-1089

2001

Volltextzugriff (PDF)

Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease

Journal of neuroimmunology, 1997-04, Vol.74 (1), p.55-61

1997

Volltextzugriff (PDF)

14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis

Neurology, 2001-08, Vol.57 (4), p.722-724

2001

Volltextzugriff (PDF)

Anticipation of age at onset in multiple sclerosis: methodologic pitfalls

Acta neurologica Scandinavica, 2010-06, Vol.121 (6), p.426-428

2010

Volltextzugriff (PDF)

An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain

Multiple sclerosis, 2007-07, Vol.13 (6), p.800-804

2007

Volltextzugriff (PDF)

CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS

Journal of neurology, 2004-10, Vol.251 (10), p.1278-1279

2004

Volltextzugriff (PDF)

Sodium intake and multiple sclerosis activity and progression in BENEFIT

Annals of neurology, 2017-07, Vol.82 (1), p.20-29

2017

Volltextzugriff (PDF)

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Lancet neurology, 2008-10, Vol.7 (10), p.903-914

2008

Volltextzugriff (PDF)

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain

Multiple sclerosis, 2012-06, Vol.18 (2_suppl), p.35-39

2012

Volltextzugriff (PDF)

The costs of a multiple sclerosis relapse in Catalonia (Spain)

Neurología (Barcelona, Spain), 2006-09, Vol.21 (7), p.341-347

2006

Volltextzugriff (PDF)

Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study

Acta neurologica Scandinavica, 2003-01, Vol.107 (1), p.7-11

2003

Volltextzugriff (PDF)

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

Neurology, 2014-04, Vol.82 (17), p.1491-1498

2014

Volltextzugriff (PDF)

Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain

Acta neurologica Scandinavica, 2000-10, Vol.102 (4), p.209-217

2000

Volltextzugriff (PDF)

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Lancet neurology, 2010-04, Vol.9 (4), p.381-390

2010

Volltextzugriff (PDF)

T cell subsets in multiple sclerosis: a serial study

Acta neurologica Scandinavica, 1995-11, Vol.92 (5), p.361-368

1995

Volltextzugriff (PDF)

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Lancet neurology, 2009-11, Vol.8 (11), p.987-997

2009

Volltextzugriff (PDF)

1 – 25 von 152

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(152)

Sprache

Englisch
(124)
Spanisch
(34)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Association of HLA-DRB115 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort

Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study)

Effect of glatiramer acetate (Copaxone ®) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: A longitudinal study

HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population

Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS

Anticipation of age at onset in familial multiple sclerosis

Multiple sclerosis and cognitive decline: is ApoE-4 a surrogate marker?

Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases

MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS

Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease

14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis

Anticipation of age at onset in multiple sclerosis: methodologic pitfalls

An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain

CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS

Sodium intake and multiple sclerosis activity and progression in BENEFIT

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain

The costs of a multiple sclerosis relapse in Catalonia (Spain)

Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study

Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

T cell subsets in multiple sclerosis: a serial study

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Aktive Filter

Suchergebnisse filtern